Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33^rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, being held March 27-31, 2024 in Kyoto, Japan.

The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.

The three oral presentations provide interim data from Parts 3 and 4 of Aligos’ ALG-000184 Phase 1 extended dosing study showing consistent, potent antiviral activity across different cohorts of untreated CHB patients receiving once daily doses of ALG-000184 as monotherapy or in combination with entecavir (ETV).

“We are pleased to present these additional Phase 1 data for ALG-055009 and ALG-000184 at APASL 2024. After the recent initiation of our Phase 2a HERALD study of ALG-055009 in MASH subjects, we remain encouraged by the data presented showing a favorable safety profile and strong evidence of target engagement, as shown by induction of sex hormone binding globulin and lowering of atherogenic lipids. We continue to believe our molecule has the potential to be best-in-class,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “In addition, the three ALG-000184 oral presentations demonstrate a consistent effect in the reduction of key viral markers. These promising results affirm our belief that this compound will play an essential role in the future treatment of hepatitis B.”

Details of the presentations are as follows:

ALG-055009: Potential best-in-class small molecule THR-β agonist for metabolic dysfunction-associated steatohepatitis (MASH)

• Poster Presentation Title: Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a THR-β Agonist, in Hyperlipidemic Subjects
  • Presented by Megan Fitzgerald, Ph.D.
  • March 28, 2024 at 5:10pm GMT+9
    

ALG-000184: Potential best-in-class small molecule CAM-E for chronic hepatitis B (CHB)

• Oral Presentation Title: ALG-000184 (300mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB
  • Presented by Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
  • March 28, 2024 at 9:30am GMT+9